Navigation Links
BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
Date:1/3/2008

ming of decisions by regulatory authorities concerning marketing applications, labeling and pricing for Aldurazyme and manufacturing facilities to be used for Aldurazyme; the companies' ability to obtain and maintain adequate patent and other proprietary rights protection for Aldurazyme; and those factors detailed in BioMarin's and Genzyme's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2006 Annual Report on Form 10-K, as amended, the factors contained in BioMarin's reports on Form 8-K, and the factors discussed under the caption "Risk Factors" in Genzyme's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. Neither BioMarin nor Genzyme is under any obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R) is a registered trademark of BioMarin Pharmaceutical Inc.

Genzyme(R) is a registered trademark of Genzyme Corporation.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

All rights reserved.

Contact:

BioMarin Genzyme

Investors Investors

Eugenia Shen Sally Curley

(415) 506-6570 (617) 768-6140

Media Media

Susan Berg Maria Cantor

(415) 506-6594 (617) 768-6690


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
2. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
3. BioMarin to Present at the BioCentury NewsMakers Conference
4. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
5. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
6. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
7. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
8. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme Launches Cholestagel(R) in Europe
11. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 /PRNewswire-iReach/ -- Maxim Peptide, a website that ... used solely in scientific experiments, is currently celebrating its ... business, Maxim Peptide, which was created by the founders ... and updated website that now features a special deals ... updated with fascinating articles about peptide research, including a ...
(Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its new ... GLOBAL MARKETS , the global market for digital polymerase ... 2013. This is estimated to grow to $490 billion ... (CAGR) of 28.6%. , New digital PCR technology has ... the broader PCR field. The opportunities presented by this ...
(Date:7/11/2014)...  Researchers have pioneered a revolutionary new way ... called Virtual Finger, allows scientists to move through ... synapses using the flat surface of their computer ... studies orders of magnitude more efficient, saving time, ... many areas of experimental biology. The software and ...
(Date:7/10/2014)... Canada (PRWEB) July 10, 2014 ... present in very low abundance and are often ... challenging and time-consuming. , Join presenters Dr. Rowel ... and Dr. John Anders, Head of Quality at ... spectrometer-based approach that can speed detection and quantitation ...
Breaking Biology Technology:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2
... Everyone would like MDs to have the best education ... in the April 4 issue of the journal Academic ... how to incorporate this understanding into real world education, particularly ... tried and true teaching strategies. Now, knowing what is happening ...
... March 30, 2011 Spherix Incorporated (Nasdaq: ... in diabetes, metabolic syndrome and atherosclerosis and provider of ... and pharmaceutical companies – today reported financial results for ... Recent and Upcoming Highlights Pharmaceutical ...
... 30, 2011 EntreMed, Inc. (Nasdaq: ENMD ... treatment of cancer, today reported results for the three ... (Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO) For fiscal year ... for fiscal 2009.  For the year ended December 31, ...
Cached Biology Technology:Brain scientists offer medical educators tips on the neurobiology of learning 2Brain scientists offer medical educators tips on the neurobiology of learning 3Brain scientists offer medical educators tips on the neurobiology of learning 4Brain scientists offer medical educators tips on the neurobiology of learning 5Spherix Announces 2010 Financial Results 2Spherix Announces 2010 Financial Results 3Spherix Announces 2010 Financial Results 4Spherix Announces 2010 Financial Results 5Spherix Announces 2010 Financial Results 6Spherix Announces 2010 Financial Results 7EntreMed Reports Fourth Quarter and Year-End 2010 Financial Results 2EntreMed Reports Fourth Quarter and Year-End 2010 Financial Results 3EntreMed Reports Fourth Quarter and Year-End 2010 Financial Results 4
(Date:7/13/2014)... more effective treatments for cachexia, a profound wasting of ... cancer patients, raising their risk of death, according to ... been tried to reverse the condition, which may cause ... but none have had great success. , Scientists reporting ... Nature , led by Bruce Spiegelman, PhD, demonstrated that ...
(Date:7/11/2014)... for Bone and Mineral Research awarded Michael F. Holick, ... with the 2014 Louis V. Avioli Award. Holick, a ... internationally known for revolutionizing the understanding of vitamin D ... award honors a member of the American Society for ... bone and mineral basic research. It is named for ...
(Date:7/11/2014)... 10, 2014---A team of researchers from The Chinese University ... a gene of wild soybean linked to salt tolerance, ... in saline soil. This study published online in ... novel genomic information for crop improvement. , Soybean is ... and human selection, cultivated soybeans have less genetic diversities ...
Breaking Biology News(10 mins):Antibody halts cancer-related wasting condition 2Antibody halts cancer-related wasting condition 3BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2BGI reports a novel gene for salt tolerance found in wild soybean 2
... international team of scientists, led by researchers at the ... crucial missing link in the search for the origin ... missing link is the natural reservoir of the virus, ... southern Cameroon. The findings provide important clues to how ...
... wildly different pathogens ?one that infects vegetables, the other ... to get their disease-causing proteins into the cells of ... State and Northwestern universities report in a study published ... The scientists were surprised to learn that the pathogen ...
... shows motion and door sensors placed in elders' homes ... memory changes that are early signs of dementia. , ... International Conference on Alzheimer's Disease and Related Disorders in ... may be a reliable way of assessing changes in ...
Cached Biology News:UAB researchers confirm HIV-1 originated in wild chimpanzees 2Malaria, potato famine pathogen share surprising trait 2In-home sensors spot dementia signs in elderly 2In-home sensors spot dementia signs in elderly 3
... products ATP-Free using Mo Bio luciferase assay. Mo ... service that will allow you to certify your ... and enable you to deliver them to your ... ATP detection limit is 3.5 x 10-12 /l, ...
... provides a comprehensive microarray service for ... embedded within non-coding RNAs (ncRNAs) using ... probe design, which enables highly sensitive ... RNAs (1). This comprehensive service includes ...
Best pricing for 100mg-1.0g scales. Phosphopeptides are our specialty....
... For knockdown of all human, mouse, ... , Genomewide, predesigned siRNAs for ... , Ready-to-use, convenient matching solutions ... Cost-effective RNAi and downstream ...
Biology Products: